Sector News

Germany's CompuGroup makes takeover approach to Agfa

October 28, 2016
Life sciences

German medical software company CompuGroup Medical has approached Belgian graphics group Agfa-Gevaert about a possible takeover, the two companies said on Friday.

Agfa makes medical IT products, which would add to CompuGroup’s range of software for doctors’ offices, pharmacies and hospitals, and also has a portfolio of other products including X-ray machines.

The combined company would have annual sales of more than 3 billion euros ($3.3 billion).

CompuGroup said it had given Agfa’s board of directors a non-binding indication of interest but said it was not certain that it would end up making a firm offer.

“The discussions between the companies are at an early stage. No response has been given to the indication of interest and CompuGroup Medical SE has not been able to verify or discuss any of the assumptions and conditions underlying its indication of interest,” CompuGroup said.

Agfa, whose market value has shrunk by a third to 616 million euros this year, said its board would evaluate CompuGroup’s approach carefully.

The news sent shares in Agfa up 6.2 percent to a six-month high of 3.80 euros.

CompuGroup shares were down 3.7 percent in early trade, with traders citing concerns that the German company would be overtaxing itself with a takeover of Agfa.

“We think a takeover offer by CompuGroup will only occur if they have a solution for Agfa Graphics and the 1.25 billion euros pension liabilities in hand,” analysts at KBC said in a note to clients.

CompuGroup has grown through a series of bolt-on acquisitions in recent years, most recently buying a majority in Vega, an Italian distributor of its software, last month.

Agfa, which in 2004 sold its eponymous camera film business which made it a household name, is active in the printing and medical imaging business.

Its healthcare business accounts for about 40 percent of its 2.6 billion euros in annual revenue. ($1 = 0.9158 euros)

By Maria Sheahan and Robert-Jan Bartunek

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.